Literature DB >> 22385476

Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Deepak B Salunke1, Nikunj M Shukla, Euna Yoo, Breanna M Crall, Rajalakshmi Balakrishna, Subbalakshmi S Malladi, Sunil A David.   

Abstract

Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine (PAM(2)CS) compounds are potential vaccine adjuvants. We had previously determined that at least one acyl group of optimal length (C(16)) and an appropriately orientated ester carbonyl group is essential for TLR2-agonistic activity. We now show that these structurally simpler analogues display agonistic activities with human, but not murine, TLR2. SAR studies on the monoacyl derivatives show that the optimal acyl chain length is C(16), and aryl substituents are not tolerated. A variety of alkyl and acyl substituents on the cysteine amine were examined. All N-alkyl derivatives were inactive. In contradistinction, short-chain N-acyl analogues were found to be highly active, with a clear dependence on the chain length. A cysteine N-acetyl analogue was found to be the most potent (EC(50): 1 nM), followed by the N-butyryl analogue. The N-acetyl analogue is human TLR2-specific, with its potency comparable to that of PAM(2)CS.
© 2012 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22385476      PMCID: PMC3325328          DOI: 10.1021/jm3000533

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  35 in total

Review 1.  Vaccines in historic evolution and perspective: a narrative of vaccine discoveries.

Authors:  M R Hilleman
Journal:  Vaccine       Date:  2000-02-14       Impact factor: 3.641

Review 2.  Toll-like receptors and innate immunity.

Authors:  S Akira
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

Review 3.  TLR signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

Review 4.  Structures of TLR-ligand complexes.

Authors:  Mi Sun Jin; Jie-Oh Lee
Journal:  Curr Opin Immunol       Date:  2008-07-02       Impact factor: 7.486

5.  Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.

Authors:  Tobias Seyberth; Söhnke Voss; Roland Brock; Karl-Heinz Wiesmüller; Günther Jung
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

6.  Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.

Authors:  Rehman Ukani; Tyler C Lewis; Timothy P Day; Wenyan Wu; Subbalakshmi S Malladi; Hemamali J Warshakoon; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2011-11-09       Impact factor: 2.823

Review 7.  A compendium of vaccine adjuvants and excipients.

Authors:  F R Vogel; M F Powell
Journal:  Pharm Biotechnol       Date:  1995

8.  TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation.

Authors:  Anne Cottalorda; Claire Verschelde; Antoine Marçais; Martine Tomkowiak; Philippe Musette; Satoshi Uematsu; Shizuo Akira; Jacqueline Marvel; Nathalie Bonnefoy-Berard
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

9.  The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood.

Authors:  Clare E Bryant; A Ouellette; K Lohmann; M Vandenplas; J N Moore; D J Maskell; B A Farnfield
Journal:  Vet Immunol Immunopathol       Date:  2007-01-31       Impact factor: 2.046

10.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.

Authors:  Matthew R Kimbrell; Hemamali Warshakoon; Jens R Cromer; Subbalakshmi Malladi; Jennifer D Hood; Rajalakshmi Balakrishna; Tandace A Scholdberg; Sunil A David
Journal:  Immunol Lett       Date:  2008-04-18       Impact factor: 3.685

View more
  20 in total

1.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

Review 2.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

3.  TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

Authors:  Nicholas J Laping; Michael P DeMartino; Joshua E Cottom; Jeffrey M Axten; John G Emery; Jeffrey H Guss; Miriam Burman; James J Foley; Mui Cheung; Allen Oliff; Sanjay Kumar
Journal:  Blood Adv       Date:  2017-12-08

4.  Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Authors:  Deepak B Salunke; Seth W Connelly; Nikunj M Shukla; Alec R Hermanson; Lauren M Fox; Sunil A David
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

5.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

6.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

7.  Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Authors:  Hari Prasad Kokatla; Euna Yoo; Deepak B Salunke; Diptesh Sil; Cameron F Ng; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Lauren M Fox; Sunil A David
Journal:  Org Biomol Chem       Date:  2013-02-21       Impact factor: 3.876

8.  Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.

Authors:  Deepak B Salunke; Euna Yoo; Nikunj M Shukla; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Katelyn J Serafin; Victor W Day; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2012-09-07       Impact factor: 7.446

9.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

Review 10.  Targeting Toll-like receptors with small molecule agents.

Authors:  Xiaohui Wang; Christina Smith; Hang Yin
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.